| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41582-019-0240-Y |
| P698 | PubMed publication ID | 31420598 |
| P50 | author | Paul M. Matthews | Q43864655 |
| P2860 | cites work | The innate immune system in demyelinating disease | Q24597958 |
| An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 | Q24599479 | ||
| Iron-based superparamagnetic nanoparticle contrast agents for MRI of infection and inflammation | Q26830874 | ||
| Structural and functional features of central nervous system lymphatic vessels | Q27316769 | ||
| Brain barriers: Crosstalk between complex tight junctions and adherens junctions | Q28083498 | ||
| Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis | Q28252596 | ||
| Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging | Q28259083 | ||
| Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis | Q28284268 | ||
| Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study | Q28288363 | ||
| Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes | Q28299872 | ||
| Neuroinflammatory component of gray matter pathology in multiple sclerosis | Q29398383 | ||
| Axonal transection in the lesions of multiple sclerosis | Q29615585 | ||
| Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain | Q30624704 | ||
| Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets | Q30640097 | ||
| A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra | Q30698264 | ||
| Multiple sclerosis | Q83785437 | ||
| Identification of Chronic Active Multiple Sclerosis Lesions on 3T MRI | Q88561420 | ||
| The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis | Q88698716 | ||
| MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course | Q90313602 | ||
| Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions | Q90632610 | ||
| PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R) | Q91010143 | ||
| Conventional DCs sample and present myelin antigens in the healthy CNS and allow parenchymal T cell entry to initiate neuroinflammation | Q91209444 | ||
| Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18F-JNJ-64413739, a PET Radioligand for P2X7 Receptors | Q91409466 | ||
| MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment. | Q30798662 | ||
| Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. | Q30960696 | ||
| MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update | Q30981999 | ||
| A practical review of the neuropathology and neuroimaging of multiple sclerosis. | Q31062386 | ||
| Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society | Q31123447 | ||
| Imaging as an Outcome Measure in Multiple Sclerosis | Q31134617 | ||
| Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging | Q31140002 | ||
| Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review | Q31145119 | ||
| The role of magnetic resonance techniques in understanding and managing multiple sclerosis | Q32067232 | ||
| The use of MR imaging as an outcome measure in multiple sclerosis clinical trials | Q33391629 | ||
| Neurotoxic reactive astrocytes are induced by activated microglia | Q33602850 | ||
| Complement activation in multiple sclerosis plaques: an immunohistochemical analysis | Q33722349 | ||
| Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study | Q33729262 | ||
| Pathologic heterogeneity persists in early active multiple sclerosis lesions | Q33804184 | ||
| The neuropathological basis of clinical progression in multiple sclerosis | Q34188436 | ||
| MP2RAGE multiple sclerosis magnetic resonance imaging at 3 T. | Q34250705 | ||
| Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. | Q34324660 | ||
| 11C-acetate PET imaging in patients with multiple sclerosis | Q34450336 | ||
| Cortical relapses in multiple sclerosis | Q34467914 | ||
| Iron and neurodegeneration in the multiple sclerosis brain | Q34470577 | ||
| Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis | Q34472457 | ||
| An updated histological classification system for multiple sclerosis lesions | Q34547552 | ||
| Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers. | Q34718044 | ||
| Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives | Q35182733 | ||
| Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients | Q35744057 | ||
| Inflammatory cortical demyelination in early multiple sclerosis | Q35764685 | ||
| MicroRNA Expression Patterns in Human Astrocytes in Relation to Anatomical Location and Age. | Q35902282 | ||
| Cortical lesions and brain atrophy in MS. | Q36127222 | ||
| Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. | Q36218017 | ||
| Inflammatory demyelination is not central to the pathogenesis of multiple sclerosis | Q36299392 | ||
| Microglia in the aging brain | Q36465314 | ||
| Regulation of cerebrospinal fluid (CSF) flow in neurodegenerative, neurovascular and neuroinflammatory disease | Q36586281 | ||
| The neuropathology and cerebrovascular mechanisms of dementia | Q36593201 | ||
| MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter | Q45242899 | ||
| TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis | Q45363125 | ||
| Comparison of rates of reported adverse events associated with i.v. iron products in the United States | Q45792335 | ||
| Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. | Q45818131 | ||
| Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. | Q45916675 | ||
| Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases | Q47291761 | ||
| Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts | Q47339103 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. | Q47432979 | ||
| Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. | Q47596113 | ||
| Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. | Q47623982 | ||
| Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies | Q47643909 | ||
| (11)C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than (11)C-( R)-PK11195. | Q47771193 | ||
| Achievements and obstacles of remyelinating therapies in multiple sclerosis. | Q47835493 | ||
| Progressive MS trials: Lessons learned | Q47892257 | ||
| Ten Things You Might Not Know about Iron Oxide Nanoparticles | Q48146534 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease | Q48243608 | ||
| A new view of the cortex, new insights into multiple sclerosis | Q48253812 | ||
| 11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis | Q48259790 | ||
| Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. | Q48411197 | ||
| Neocortical neuronal, synaptic, and glial loss in multiple sclerosis | Q48413281 | ||
| Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study | Q48440605 | ||
| Thalamic neurodegeneration in multiple sclerosis | Q48459257 | ||
| Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study | Q48661873 | ||
| Immunopathology of secondary-progressive multiple sclerosis | Q48713004 | ||
| In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET. | Q48732605 | ||
| Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions | Q48791086 | ||
| Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts | Q48797418 | ||
| Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis | Q48851784 | ||
| Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
| Nuclear magnetic resonance imaging of the brain in multiple sclerosis | Q49158364 | ||
| Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis | Q50021192 | ||
| Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. | Q50035367 | ||
| Gadolinium-Based Contrast Agent-Related Toxicities. | Q50420726 | ||
| Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. | Q50656963 | ||
| Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis. | Q50982264 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. | Q51666856 | ||
| Disease-Modifying Treatment in Progressive Multiple Sclerosis. | Q52600478 | ||
| TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. | Q52663508 | ||
| Evaluation of 11C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain. | Q52663697 | ||
| Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination. | Q54229364 | ||
| Multiple Sclerosis: Mechanisms and Immunotherapy. | Q55060344 | ||
| The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. | Q55449054 | ||
| Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging | Q56774466 | ||
| Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies | Q57152501 | ||
| CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature | Q57446154 | ||
| The influence of brain iron and myelin on magnetic susceptibility and effective transverse relaxation - A biochemical and histological validation study | Q57496942 | ||
| The glymphatic pathway in neurological disorders | Q57788282 | ||
| Cellular Sources and Regional Variations in the Expression of the Neuroinflammatory Marker Translocator Protein (TSPO) in the Normal Brain | Q58749701 | ||
| Innate immune memory in the brain shapes neurological disease hallmarks | Q59071784 | ||
| Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: A neuropathological study | Q61478747 | ||
| Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone | Q61699071 | ||
| Pro-inflammatory activation of microglia in the brain of patients with sepsis. | Q61709413 | ||
| Optimization of molecularly targeted MRI in the brain: empirical comparison of sequences and particles. | Q64967078 | ||
| Evaluation of Two Potent and Selective PET Radioligands to Image COX-1 and COX-2 in Rhesus Monkeys. | Q64983754 | ||
| Major differences in the dynamics of primary and secondary progressive multiple sclerosis | Q68201259 | ||
| Neurochemical Correlates of Sympathetic Activation during Severe Alcohol Withdrawal | Q72106768 | ||
| Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study | Q72816213 | ||
| The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity | Q73119445 | ||
| Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis | Q74227216 | ||
| Does high-field MR imaging improve cortical lesion detection in multiple sclerosis? | Q80579422 | ||
| Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: an exploratory study | Q83519256 | ||
| Systemic infections and inflammation affect chronic neurodegeneration | Q36707203 | ||
| Inflammatory cell migration into the central nervous system: a few new twists on an old tale | Q36771887 | ||
| Lesion Heterogeneity on High-Field Susceptibility MRI Is Associated with Multiple Sclerosis Severity. | Q37172391 | ||
| The relation between inflammation and neurodegeneration in multiple sclerosis brains. | Q37181308 | ||
| Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain | Q37221310 | ||
| Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain | Q37306518 | ||
| Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI | Q37414011 | ||
| Predicting responders to therapies for multiple sclerosis | Q37606292 | ||
| M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination | Q37687158 | ||
| Disruption of central nervous system barriers in multiple sclerosis | Q37771484 | ||
| Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. | Q37860106 | ||
| Progressive multiple sclerosis: pathology and pathogenesis | Q38046113 | ||
| Pathology of multiple sclerosis and related inflammatory demyelinating diseases | Q38186200 | ||
| The central role of mitochondria in axonal degeneration in multiple sclerosis | Q38239792 | ||
| Pathological mechanisms in progressive multiple sclerosis | Q38378846 | ||
| Advanced imaging tools to investigate multiple sclerosis pathology | Q38394282 | ||
| Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice | Q38587671 | ||
| Assessing Repair in Multiple Sclerosis: Outcomes for Phase II Clinical Trials. | Q38659598 | ||
| Central nervous system inflammation across the age span. | Q38795661 | ||
| Neuronal loss, demyelination and volume change in the multiple sclerosis neocortex | Q38931740 | ||
| Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis | Q39013846 | ||
| Endothelial cells and lymphatics at the interface between the immune and central nervous systems: implications for multiple sclerosis | Q39190253 | ||
| Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. | Q39211049 | ||
| In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195. | Q39213875 | ||
| Imaging Markers for Monitoring Disease Activity in Multiple Sclerosis. | Q39247449 | ||
| Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. | Q40014398 | ||
| Role of the mucosal integrin alpha(E)(CD103)beta(7) in tissue-restricted cytotoxicity. | Q40150917 | ||
| FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection. | Q40450407 | ||
| Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. | Q41185283 | ||
| Age-associated changes in rat immune system: lessons learned from experimental autoimmune encephalomyelitis | Q42199650 | ||
| A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. | Q42847184 | ||
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. | Q43227358 | ||
| Serum levels of CXCL13 are elevated in active multiple sclerosis | Q43266829 | ||
| Thymic involution and proliferative T-cell responses in multiple sclerosis. | Q43791918 | ||
| P433 | issue | 10 | |
| P304 | page(s) | 582-593 | |
| P577 | publication date | 2019-08-16 | |
| P1433 | published in | Nature Reviews Neurology | Q2079285 |
| P1476 | title | Chronic inflammation in multiple sclerosis - seeing what was always there | |
| P478 | volume | 15 |
| Q90481528 | Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging |
| Q99711311 | Evidence That Cannabis Exposure, Abuse, and Dependence Are Related to Glutamate Metabolism and Glial Function in the Anterior Cingulate Cortex: A 1H-Magnetic Resonance Spectroscopy Study |
| Q91971879 | Multispecific drugs herald a new era of biopharmaceutical innovation |
| Q97067402 | Visualizing the Central Nervous System: Imaging Tools for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders |
| Q92924571 | White Matter and Neuroprotection in Alzheimer's Dementia |
Search more.